News

PipelineReview.com1h

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung ...
PipelineReview.com1h

Abcentra LLC Announces First Patient Dosed in Phase 2b “FORTIFY” Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease

LOS ANGELES, CA, USA I August 12, 2025 I Abcentra LLC, a clinical-stage biopharmaceutical company pioneering targeted therapies for cardiovascular ...
PipelineReview.com1h

Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH

HUNTINGTON, NY, USA I August 12, 2025 I Sen-Jam Pharmaceutical today announced significant progress in advancing its innovative immuno-regulator platform ...
PipelineReview.com1h

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

SEOUL, South Korea I August 13, 2025 I Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) ...
PipelineReview.com1h

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates ...
PipelineReview.com1h

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

SOUTH SAN FRANCISCO, CA, USA I August 12, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...